Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 394

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 394
---
 to the Public Warrants except that they will be non-redeemable and exercisable on a cashless basis for as long as the Private Warrants are held by Cantor, the representative of the underwriters, or its permitted transferees. Additionally, for so long as the Private Warrants are held by Cantor or its designees or affiliates, they may not be exercised after five years from the closing of the IPO.

<div align='center'>218</div>

TABLE OF CONTENTS

### BENEFICIAL OWNERSHIP OF SECURITIES
The following table sets forth information regarding: (i) the actual beneficial ownership of Iris common stock as of January 2, 2025 based on information obtained from the persons named below, with respect to the beneficial ownership of Iris common stock, which is prior to the consummation of the Business Combination and the other transactions contemplated by the Business Combination Agreement and (ii) expected beneficial ownership of ParentCo Common Stock immediately following the consummation of the Business Combination and the other transactions contemplated by the Business Combination Agreement, assuming that: (x) no shares of Iris Class A Common Stock are redeemed and (y) assuming that all shares of Iris Class A Common Stock are redeemed for cash and excluding the potential dilutive effect of the exercise of the ParentCo warrants after the closing held by:

•

each person or “group” (as such term is used in Section 13(d)(3) of the Exchange Act) who is a beneficial owner of more than 5% of our outstanding shares of common stock or is expected to be the beneficial owner of more than 5% of ParentCo’s outstanding shares of common stock following the closing;

•

each of Iris’s current named executive officers and directors;

•

each person who will become a named executive officer or a director of ParentCo upon the consummation of the Business Combination;

•

all of Iris’s current executive officers and directors as a group; and

•

all of ParentCo’s executive officers and directors as a group after the consummation of the Business Combination.

Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. The table below does not include the shares of Iris Class A Common Stock underlying the private placement warrants held by the Sponsor, the Public Warrants to be issued